Radioembolization

In November 2024, the following ongoing mini-HTA assessments for cardiovascular, diagnostic imaging, e-health, gastrointestinal, in-vitro diagnostics, interventional radiology, men’s health, pulmonary and airways, robotic surgery, and some other fields are evaluated as a part of a framework for the managed introduction of innovations "New Methods" in Norway.

In June 2024, the following ongoing mini-HTA assessments for cardiovascular, diagnostic imaging, e-health, endoscopy, gastrointestinal, in-vitro diagnostics, men’s health, neurology and neurosurgery, neuromodulation, peripheral vascular, pulmonary and airways, robotic surgery, and some other fields are evaluated as a part of a framework for the managed introduction of innovations "New Methods" in Norway.

The French National Authority for Health (HAS) released new decisions about add-on and medical aid reimbursement of many medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in August 2020. Decisions concern cartilage implant, energy return prosthetic feet, and Yttrium-90 microspheres.

The French National Authority for Health (HAS) released new decisions about add-on and medical aid reimbursement of medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in January 2019. The decisions were made for eighteen medical devices.

SIRT is not routinely commissioned in England. In 2013 NHS England commissioned an evaluation of SIRT for colorectal liver metastases and intrahepatic cholangiocarcinoma within registry in England, complemented by systematic literature review and de novo economic analysis (Commissioning Through Evaluation). In July 2017, NICE prepared a final report for NHS England, which was made public on 12th of October 2017.

Dutch National Health Care Institute (Zorginstituut Nederland) has confirmed scope of surveillance on implementation of radioembolization with Yttrium-90 microspheres as salvage therapy for patients with non-resectable liver metastases of colorectal cancer origin in the Netherlands. The focus will be on evolution of cost and volume of procedures, concentration of care in few designated centers and implementation of clinical protocol for use of procedure.